Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 500-515.e3
Open Access | Times Cited: 292

Showing 1-25 of 292 citing articles:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 673
Harnessing cytokines and chemokines for cancer therapy
David Propper, Frances R. Balkwill
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 237-253
Closed Access | Times Cited: 603
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 539
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 704-712
Open Access | Times Cited: 314
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Haozhen Lv, Xiao Liu, Xuanhao Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 183
Mechanisms of immune activation and regulation: lessons from melanoma
Shelly Kalaora, Adi Nagler, Jennifer A. Wargo, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 4, pp. 195-207
Closed Access | Times Cited: 166
Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
Sarah C. Sasson, Stephanie Slevin, Vincent Cheung, et al.
Gastroenterology (2021) Vol. 161, Iss. 4, pp. 1229-1244.e9
Open Access | Times Cited: 145
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2602-2619
Open Access | Times Cited: 124
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Juan Dubrot, Peter P. Du, Sarah Kate Lane-Reticker, et al.
Nature Immunology (2022) Vol. 23, Iss. 10, pp. 1495-1506
Closed Access | Times Cited: 124
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Darya Alizadeh, Robyn A. Wong, Sharareh Gholamin, et al.
Cancer Discovery (2021) Vol. 11, Iss. 9, pp. 2248-2265
Open Access | Times Cited: 122
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Dimitra Kerdidani, Emmanouil Aerakis, Kleio‐Maria Verrou, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 2
Open Access | Times Cited: 118
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Inês Pires da Silva, Peter A. Johansson, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 88-102.e7
Open Access | Times Cited: 112
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Ola Habanjar, Rea Bingula, Caroline Decombat, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4002-4002
Open Access | Times Cited: 110
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine Huang, et al.
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114112-114112
Open Access | Times Cited: 95
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A. Martín-Serrano, Benjamin Kepecs, Miguel Torres‐Martín, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 736-748
Open Access | Times Cited: 90
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Jason M. Schenkel, Kristen E. Pauken
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 807-823
Open Access | Times Cited: 60
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Madeleine Benguigui, Tim J. Cooper, Prajakta Kalkar, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 253-265.e12
Open Access | Times Cited: 55
The hallmarks of cancer immune evasion
Claudia Galassi, Timothy A. Chan, Ilio Vitale, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1825-1863
Closed Access | Times Cited: 49
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam J. Schoenfeld, Darwin Ye, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 209-224.e9
Open Access | Times Cited: 39
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 37
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
Sameeha Jilani, Justin D. Saco, Edurne Mugarza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 6
Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment
Flávia Castro, Marta L. Pinto, Catarina Leite Pereira, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 621-635
Open Access | Times Cited: 3
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
Jian Hu, Dongxu Qiu, Anze Yu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 99
Page 1 - Next Page

Scroll to top